Back to results
US 2023/0416829 A1Published application
Immunotherapy Response Signature
AssigneeCaris MPI, Inc.
InventorsJim Abraham, David Spetzler
Life of this patent
Estimating the term…
Abstract
Comprehensive molecular profiling provides a wealth of data concerning the molecular status of patient samples. Such data can be compared to patient response to treatments to identify biomarker signatures that predict response or non-response to such treatments. This approach has been applied to identify biomarker signatures that predict cancer patient benefit from immunotherapy such as checkpoint inhibitor therapy.
Claims41
A method of treating a cancer in a subject, the method comprising:
- (a) obtaining a biological sample comprising cells and/or cell free materials derived from the cancer in the subject;
- (b) performing an assay to assess a copy number of chromosome 9 or a portion thereof in the biological sample;
- and
- (c) administering a treatment for the cancer to the subject based on the assessment of step (b).
1 more element
A method of selecting a treatment for a subject who has a cancer, the method comprising:
- (a) obtaining a biological sample comprising cells and/or cell free material derived from the cancer in the subject;
- (b) performing an assay to assess a copy number of chromosome 9 or a portion thereof in the biological sample, optionally wherein the assay comprises at least one of sequencing, hybridization, amplification, next-generation sequencing, whole-genome sequencing (WGS), whole-exome sequencing (WES), whole-transcriptome sequencing (WTS), in situ hybridization (ISH), comparative genomic hybridization (CGH), high-resolution array comparative genomic hybridization (aCGH), microarray-based platforms, and PCR techniques;
- and
- (c) selecting a treatment for the cancer to the subject based on the copy number of chromosome 9 or the portion thereof in (b).
1 more element
Dependencies are inferred from the claim text.